Exploring individual-specific synchrony in therapeutic relationships for depression
Official title: An Individual-specific Understanding of How Synchrony Becomes Curative
Run by University of Haifa · NCT06749392 · Data updated 2026-11-12
This study is trying to see if finding unique patterns in how patients and therapists connect can help people with depression feel better and improve their treatment outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 78 (estimated) |
| Sponsor | University of Haifa Academic / other |
| Locations | 1 site (Haifa) |
| Status | Recruiting |
| Started | November 22, 2025 |
| Main results expected | March 30, 2030 |
| Study ends | March 30, 2030 |
| Registry record updated | November 24, 2025 |
| Trial ID | NCT06749392 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 65 who are diagnosed with Major Depressive Disorder and have stable psychiatric medication dosages.
✕Probably not a fit
Patients at risk of suicide, those with substance abuse disorders, or individuals currently undergoing psychotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the concept of synchrony as a personalized mechanism that may facilitate therapeutic change in individuals with Major Depressive Disorder. It aims to identify unique synchrony signatures for each participant and explore how these signatures relate to their mental health and treatment outcomes. The research will assess the stability of these synchrony signatures over time and their potential impact on the therapeutic relationship with the therapist. By understanding these dynamics, the study seeks to provide insights into improving therapeutic interventions for depression.
Why it matters
Potential benefit: If successful, this study could enhance therapeutic approaches for patients with Major Depressive Disorder by tailoring treatments based on individual synchrony signatures.
How similar studies have gone: While the concept of synchrony in therapeutic relationships is recognized, this specific approach is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current major depressive disorder based on the Diagnostic and Statistical Manual of Mental Disorders-5, and scores above 14 on the 17-item Hamilton rating scale for depression at two consecutive assessments, one week apart. * For participants using psychiatric medication, the dosage must be stable for at least three months before the beginning of the study, and they will be asked to maintain stable dosage during the treatment * Age between 18 and 65 years * Hebrew language proficiency * Provision of written informed consent. Exclusion Criteria: * Current risk of suicide or self-harm * Current substance abuse disorders * Current or past schizophrenia or psychosis, bipolar disorder, or severe eating disorder requiring medical monitoring * History of organic mental disease * Currently in psychotherapy
Where it's running
-
University of Haifa
Haifa, Israel Recruiting
Study contacts
- Study coordinator: Sigal Zilcha-Mano
- Email: sigalzil@gmail.com
- Phone: 972-8249047
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dupilumab for Major Depressive Disorder
This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.
-
Accelerated vs Standard iTBS for Major Depression
This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.
-
Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD
This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.
-
Magnesium Bisglycinate Added to Your Depression Treatment
This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.
-
Motif XCS System for treatment-resistant depression
This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.
-
A Phase 3 test of DT120 for major depressive disorder
DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.